Bal Pharma Limited (BALPHARMA.BO)
INR 120.0
(-0.87%)
INR 120.0
(-0.87%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 345.59 Million INR | 30.07% |
| 2022 | 244.99 Million INR | -2.47% |
| 2021 | 287.64 Million INR | 2.63% |
| 2020 | 257.82 Million INR | 396.49% |
| 2019 | 68.8 Million INR | -70.63% |
| 2018 | 186.92 Million INR | -8.13% |
| 2017 | 189.26 Million INR | 12.98% |
| 2016 | 178.52 Million INR | 6.68% |
| 2015 | 161.31 Million INR | -10.99% |
| 2014 | 181.96 Million INR | -2.19% |
| 2013 | 184.42 Million INR | 0.06% |
| 2012 | 172.18 Million INR | 23.27% |
| 2011 | 139.67 Million INR | 29.63% |
| 2010 | 107.75 Million INR | 161.3% |
| 2009 | 60.1 Million INR | -63.01% |
| 2008 | 111.49 Million INR | 21.94% |
| 2007 | 91.43 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 64.65 Million INR | -39.53% |
| 2023 Q1 | 72.89 Million INR | 11.67% |
| 2023 Q2 | 78.39 Million INR | 7.55% |
| 2023 Q3 | 78.89 Million INR | 0.64% |
| 2023 Q4 | 95.91 Million INR | 21.58% |
| 2023 FY | - INR | 30.07% |
| 2022 FY | - INR | -2.47% |
| 2022 Q4 | 65.27 Million INR | -1.27% |
| 2022 Q3 | 66.11 Million INR | 13.56% |
| 2022 Q2 | 58.22 Million INR | -3.04% |
| 2022 Q1 | 60.04 Million INR | 6.86% |
| 2021 Q4 | 56.19 Million INR | -19.4% |
| 2021 Q3 | 69.72 Million INR | 1.28% |
| 2021 Q2 | 68.83 Million INR | -9.7% |
| 2021 FY | - INR | 2.63% |
| 2021 Q1 | 76.23 Million INR | 33.86% |
| 2020 Q2 | 71.63 Million INR | 36.77% |
| 2020 FY | - INR | 396.49% |
| 2020 Q3 | 61.21 Million INR | -14.54% |
| 2020 Q4 | 56.94 Million INR | -6.98% |
| 2020 Q1 | 52.37 Million INR | 5471.91% |
| 2019 FY | - INR | -70.63% |
| 2019 Q2 | 18.57 Million INR | 1.94% |
| 2019 Q1 | 18.22 Million INR | -49.1% |
| 2019 Q3 | 11.13 Million INR | -40.07% |
| 2019 Q4 | 940 Thousand INR | -91.56% |
| 2018 Q4 | 35.8 Million INR | -22.6% |
| 2018 Q2 | 41.92 Million INR | -9.39% |
| 2018 FY | - INR | -8.13% |
| 2018 Q1 | 46.26 Million INR | -16.07% |
| 2018 Q3 | 46.26 Million INR | 10.36% |
| 2017 FY | - INR | 12.98% |
| 2017 Q4 | 55.12 Million INR | 0.0% |
| 2016 Q3 | 36.31 Million INR | -35.3% |
| 2016 FY | - INR | 6.68% |
| 2016 Q4 | 39.93 Million INR | 9.99% |
| 2016 Q2 | 56.11 Million INR | 36.87% |
| 2016 Q1 | 41 Million INR | 97.75% |
| 2015 Q4 | 20.73 Million INR | -61.53% |
| 2015 FY | - INR | -10.99% |
| 2015 Q1 | 20.73 Million INR | -51.73% |
| 2015 Q2 | 53.39 Million INR | 157.51% |
| 2015 Q3 | 53.89 Million INR | 0.93% |
| 2014 Q1 | 40.04 Million INR | -9.15% |
| 2014 Q4 | 42.95 Million INR | 13.87% |
| 2014 Q3 | 37.72 Million INR | -21.1% |
| 2014 FY | - INR | -2.19% |
| 2014 Q2 | 47.81 Million INR | 19.39% |
| 2013 Q1 | 44.25 Million INR | -23.42% |
| 2013 Q4 | 44.07 Million INR | -2.97% |
| 2013 FY | - INR | 0.06% |
| 2013 Q2 | 45 Million INR | 1.69% |
| 2013 Q3 | 45.42 Million INR | 0.94% |
| 2012 Q2 | 41.55 Million INR | 38.9% |
| 2012 Q1 | 29.91 Million INR | -36.24% |
| 2012 Q3 | 43.03 Million INR | 3.55% |
| 2012 Q4 | 57.78 Million INR | 34.3% |
| 2012 FY | - INR | 23.27% |
| 2011 Q3 | 31.39 Million INR | -7.94% |
| 2011 Q4 | 46.92 Million INR | 49.44% |
| 2011 FY | - INR | 29.63% |
| 2011 Q2 | 34.1 Million INR | 0.0% |
| 2010 FY | - INR | 161.3% |
| 2009 FY | - INR | -63.01% |
| 2008 FY | - INR | 21.94% |
| 2007 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | 97.25% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 49.367% |
| Sigachi Industries Limited | 883.39 Million INR | 60.879% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 94.963% |
| Medico Remedies Limited | 150.37 Million INR | -129.816% |
| Lasa Supergenerics Limited | -65.08 Million INR | 631.026% |
| Venus Remedies Limited | 711.8 Million INR | 51.448% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 109.262% |
| Alpa Laboratories Limited | 86.12 Million INR | -301.259% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 77.9% |
| Shilpa Medicare Limited | 2.58 Billion INR | 86.646% |
| Aarti Drugs Limited | 3.24 Billion INR | 89.362% |
| Lupin Limited | 36.96 Billion INR | 99.065% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.441% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.385% |
| Windlas Biotech Limited | 781.72 Million INR | 55.791% |
| Suven Life Sciences Limited | -992.78 Million INR | 134.811% |
| Eris Lifesciences Limited | 6.98 Billion INR | 95.053% |
| Valiant Laboratories Limited | 12.73 Million INR | -2612.866% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 96.298% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 112.247% |
| Ipca Laboratories Limited | 13.29 Billion INR | 97.401% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 76.634% |
| Achyut Healthcare Limited | 524 Thousand INR | -65852.672% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.75% |
| Bajaj HealthCare Limited | 444.51 Million INR | 22.254% |
| RPG Life Sciences Limited | 1.28 Billion INR | 73.032% |
| Mankind Pharma Limited | 28.09 Billion INR | 98.77% |
| Laurus Labs Limited | 8 Billion INR | 95.683% |
| Piramal Pharma Limited | 13.05 Billion INR | 97.353% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 19.681% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 99.013% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 96.406% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 96.953% |
| Unichem Laboratories Limited | 742.35 Million INR | 53.447% |
| Sequent Scientific Limited | 549.8 Million INR | 37.142% |
| Novartis India Limited | 1.26 Billion INR | 72.773% |
| Wanbury Limited | 985.49 Million INR | 64.932% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 92.611% |
| Wockhardt Limited | 1.08 Billion INR | 68.001% |
| Themis Medicare Limited | 562.6 Million INR | 38.573% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -6.842% |
| Jubilant Pharmova Limited | 8 Billion INR | 95.683% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 94.964% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.609% |
| Divi's Laboratories Limited | 25.43 Billion INR | 98.641% |
| NATCO Pharma Limited | 18.79 Billion INR | 98.161% |
| Gufic Biosciences Limited | 1.48 Billion INR | 76.657% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 86.742% |
| Ind-Swift Limited | 1.06 Billion INR | 67.552% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 88.535% |
| FDC Limited | 4.4 Billion INR | 92.149% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 517.75% |
| Granules India Limited | 8.6 Billion INR | 95.983% |
| Medicamen Biotech Limited | 245.66 Million INR | -40.679% |
| Alkem Laboratories Limited | 24.19 Billion INR | 98.572% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 85.336% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -2545.782% |
| Brooks Laboratories Limited | 41.72 Million INR | -728.202% |
| Megasoft Limited | 284.73 Million INR | -21.375% |
| ZIM Laboratories Limited | 462.09 Million INR | 25.212% |
| Strides Pharma Science Limited | 3.76 Billion INR | 90.82% |
| Neuland Laboratories Limited | 4.74 Billion INR | 92.722% |
| Morepen Laboratories Limited | 1.72 Billion INR | 79.977% |
| Hikal Limited | 2.69 Billion INR | 87.163% |
| Indoco Remedies Limited | 2.64 Billion INR | 86.944% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 91.16% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -20.237% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -97.542% |
| Hester Biosciences Limited | 539.47 Million INR | 35.939% |